Lipella Pharmaceuticals Company Leadership
| LIPO Stock | 2.80 0.16 5.41% |
Lipella Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Lipella Pharmaceuticals Common suggests that virtually all insiders are extremely bullish. Lipella Pharmaceuticals employs about 5 people. The company is managed by 5 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive.
Lipella Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-05-14 | Jonathan H Kaufman | Acquired 1250 @ 6.08 | View | ||
| 2024-03-18 | Jonathan H Kaufman | Acquired 3750 @ 6.32 | View |
Monitoring Lipella Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Lipella |
Lipella Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.9377) % which means that it has lost $0.9377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7156) %, meaning that it created substantial loss on money invested by shareholders. Lipella Pharmaceuticals' management efficiency ratios could be used to measure how well Lipella Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -1.36. In addition to that, Return On Capital Employed is likely to grow to -1.41. At this time, Lipella Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 27th of November 2024, Other Current Assets is likely to grow to about 174.6 K, while Total Assets are likely to drop about 2.8 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to grow to about 6.4 M, though Net Loss is likely to grow to (2.2 M).
Lipella Pharmaceuticals Workforce Comparison
Lipella Pharmaceuticals Common is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,104. Lipella Pharmaceuticals adds roughly 5.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Lipella Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipella Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipella Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lipella Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kaufman Jonathan H over six months ago Acquisition by Kaufman Jonathan H of 10000 shares of Lipella Pharmaceuticals at 0.759 subject to Rule 16b-3 | ||
Chancellor Michael B over six months ago Disposition of tradable shares by Chancellor Michael B of Lipella Pharmaceuticals subject to Rule 16b-3 | ||
Kaufman Jonathan H over six months ago Acquisition by Kaufman Jonathan H of 30000 shares of Lipella Pharmaceuticals at 0.7883 subject to Rule 16b-3 | ||
Kim Byong over six months ago Acquisition by Kim Byong of 25000 shares of Lipella Pharmaceuticals at 0.77 subject to Rule 16b-3 | ||
Chancellor Michael B over six months ago Acquisition by Chancellor Michael B of 144906 shares of Lipella Pharmaceuticals at 0.6901 subject to Rule 16b-3 | ||
Battleman David S over a year ago Acquisition by Battleman David S of 25000 shares of Lipella Pharmaceuticals subject to Rule 16b-3 |
Lipella Pharmaceuticals Notable Stakeholders
A Lipella Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lipella Pharmaceuticals often face trade-offs trying to please all of them. Lipella Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lipella Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael MD | Chief CoFounder | Profile | |
| Jonathan MBA | Chairman, CoFounder | Profile | |
| Michele Gruber | Director Operations | Profile | |
| Douglas CPA | Chief Officer | Profile | |
| Katie Johnston | Controller | Profile |
About Lipella Pharmaceuticals Management Performance
The success or failure of an entity such as Lipella Pharmaceuticals often depends on how effective the management is. Lipella Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lipella management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lipella management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.36) | |
| Return On Capital Employed | (1.49) | (1.41) | |
| Return On Assets | (1.29) | (1.36) | |
| Return On Equity | (1.47) | (1.40) |
Lipella Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Lipella Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lipella Pharmaceuticals within its industry.Lipella Pharmaceuticals Manpower Efficiency
Return on Lipella Pharmaceuticals Manpower
| Revenue Per Employee | 89.9K | |
| Revenue Per Executive | 89.9K | |
| Net Loss Per Employee | 923.8K | |
| Net Loss Per Executive | 923.8K | |
| Working Capital Per Employee | 608.8K | |
| Working Capital Per Executive | 608.8K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.